Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Vaccine
; 31(48): 5745-53, 2013 Nov 19.
Article
em En
| MEDLINE
| ID: mdl-24091311
Palavras-chave
APC; ART; ATP; BARC; Bio Analytical Research Corporation; CI; ELISA; GMT; HIV; HPV; HPV vaccination; HPV-16/18 AS04-adjuvanted vaccine; Human immunodeficiency virus (HIV); Human papillomavirus (HPV); IDMC; Immunogenicity; Independent Data Monitoring Committee; MPL; NOCD; PMTCT; Preventing Mother-to-Child Transmission of HIV; SAE; Safety; TVC; WHO; World Health Organisation; according-to-protocol; antigen-presenting cell; antiretroviral therapy; confidence interval; enzyme-linked immunosorbent assay; geometric mean antibody titre; human immunodeficiency virus; human papillomavirus; monophosphoryl lipid A; new-onset chronic disease; serious adverse event; total vaccinated cohort
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Adjuvantes Imunológicos
/
Infecções por Papillomavirus
/
Vacinas contra Papillomavirus
/
Hidróxido de Alumínio
/
Lipídeo A
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article